Keywords
hypoglycemic agents
DPP4
SGLT2
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the use of combined therapy of sodium-glucose cotransporter-2 inhibitors (Sodium-glucose co-transporter 2 -SGLT2) and dipeptidyl peptidase-4 (Dipeptidyl peptidase 4 -DPP4) in patients with Type 2 Diabetes Mellitus Methods: This is an integrative literature review, using databases of digital collections of scientific research and applying inclusion and exclusion criteria to select the most relevant materials. Results: The combined therapy of SGLT2 and DPP4 inhibitors proved to be effective in different settings compared to monotherapy. There was better glycemic control, weight loss, low rate of genital infections and lower risk of hypoglycemia. The exposed effects strengthen the use of a combination therapy. The mechanisms of these drugs complement the baseline treatment with metformin. It is still necessary to expand research and evaluations for the prescription of this combination for individuals with kidney and heart diseases. Final considerations: Combination treatment with a DPP4 and SGLT2 inhibitor may be an effective and safe option for T2DM patients initiating pharmacological therapy or for patients who received treatment in a single-medication format of metformin but require additional glycemic control due to the characteristic of disease progression.
References
ALVAREZ CA, et al. Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Anti-hyperglycemic Medications. Clin Pharmacol Ther. 2016; 13(11): 1478–86.
ALVES C, et al. Mecanismos Patogênicos da Doença Periodontal Associada ao Diabetes Melito. Arq Bras Endocrinol Metab 2007; 51 (7).
AMERICAN DIABETES ASSOCIATION. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41: 917–928.
ANDREW L, et al. Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes. Diabetes Care 1, 2015; 38 (3): 394–402.
BECKER RM e HEIDEMANN IB. Promoção da saúde no cuidado às pessoas com doença crônica não transmissível: revisão integrativa. Texto Contexto Enferm. 2020;29.
CENTERS FOR DISEASE CONTROL AND PREVENTION. National Diabetes Statistics Report, 2020.
CHEN M, et al. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus patients with severe renal impairment: A metaanalysis. Ren Fail. 2016; 38(4): 581–7.
CHO YK, et al. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: a systematic review and meta‐analysis. Diabetes Metab 2018; 44: 393–401.
CURTIS HJ, et al. Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017. Diabetes Obes Metab 2018; 20: 2159–2168.
DEFRONZO RA, et al. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13(1):11–26.
DEMUTH HU, et al. Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 2005; 1751(33).
GIUSTI CT e NUNES CP eficácia e eventos adversos dos inibidores de sglt2. Revista da Faculdade de Medicina de Teresópolis, 2020; 4(1).
GU N, et al. Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor. Transl Clin Pharmacol. 2020; 28(1): 17-33.
KAKU K et al. Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial. Diabetes Obes Metab. 2019; 21(1): 136-145.
KIM, ES e DEEKS, ED. Empagliflozin/Linagliptin: A Review in Type 2 Diabetes. Drugs, 2015; 75: 1547–155.
KOLB H E MARTIN S. Environmental/lifestyle factors in the pathogenesis and prevention of type 2 diabetes. BMC Med. 2017; 15(1): 13.
LI D, et al. SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab., 2018; 20: 1972– 1976.
LINGVAY I, et al. Combinação de dose fixa tripla empagliflozina, linagliptina e metformina para pacientes com diabetes tipo 2, Postgraduate Medicine, 2020; 132(4): 337-345.
MALTA DC e SILVA JR JB O Plano de Ações Estratégicas para o Enfrentamento das Doenças Crônicas Não Transmissíveis no Brasil e a definição das metas globais para o enfrentamento dessas doenças até 2025: uma revisão. Epidemiol. Serv. Saúde, 2013; 22(1): 151-164.
MIN SH et al. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis. Sci Rep., 2018; 8(1): 4466.
MUHAMMAD ABDUL-GHANI; Where Does Combination Therapy with an SGLT2 Inhibitor Plus a DPP-4 Inhibitor Fit in the Management of Type 2 Diabetes? Diabetes Care, 2015; 38(3): 373–375.
NUNES SILVA J Fisiopatologia da diabetes mellitus tipo 1 e tipo 2. Portugal, 2018; 100: 8-12.
GUTHRIE ROBERT M. Uso clínico de dipeptidil peptidase-4 e inibidores do cotransportador de sódio-glicose 2 em terapia combinada para diabetes mellitus tipo 2. Medicine, 2015; 127(5): 463-479.
SCHEEN ANDRÉ J. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. Circ Res., 2018; 122(10): 1439-1459.
SCHEEN ANDRÉ J. Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes. Clin Pharmacokinet., 2017; 56: 703–718.
TAN X, HU J. Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes. Ann Endocrinol (Paris), 2016; 77(5): 557-562.
VALLON V e THOMSON SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia, 2017; 60(2): 215–225.
WORLD HEALTH ORGANIZATION. World health statistics 2018: monitoring health for the SDGs, sustainable development goals. Geneva, 2018.
WOO V. Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option. Int J Clin Pract., 2015; 69(12): 1427-1437.
ZHENG Y, et al. Global etiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol., 2018; 4: 88-98.
ZHOU J, et al. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users. ESC Heart Fail, 2022; 9(2): 1388-1399.